Cancer market commentary: 3 highlights from ESMO (Part 1)
Commentary on key cancer data from ESMO by Stephanie Hawthorne
Commentary on key cancer data from ESMO by Stephanie Hawthorne
Novartis’ phase 3 advanced breast cancer therapy ribociclib shows promise
Rucaparib is only drug left in biotech’s pipeline.